Activation of factor XI (FXI) by thrombin in vivo plays a role in coagulation by providing an important positive feedback mechanism for additional thrombin generation. FXI is activated in vitro by thrombin, or FXIIa in the presence of dextran sulfate. In this report, we investigated the effect of ␤2-glycoprotein I (␤2GPI) on the activation of FXI. ␤2GPI bound FXI in vitro and inhibited its activation to FXIa by thrombin and FXIIa. The affinity of the interaction between ␤2GPI and FXI was equivalent to the interaction between FXI and high molecular weight kininogen. Inhibition of FXI activation occurred with lower concentrations of ␤2GPI than found in human plasma. Proteolytic clipping of ␤2GPI by plasmin abolished its inhibition of FXI activation. The results suggest a mechanism of regulation whereby physiological concentrations of ␤2GPI may attenuate thrombin generation in vivo by inhibition of FXI activation. Plasmin cleavage of ␤2GPI provides a negative feedback that counteracts its inhibition of FXI activation.
Activation of factor XI (FXI) by thrombin in vivo plays a role in coagulation by providing an important positive feedback mechanism for additional thrombin generation. FXI is activated in vitro by thrombin, or FXIIa in the presence of dextran sulfate. In this report, we investigated the effect of ␤2-glycoprotein I (␤2GPI) on the activation of FXI. ␤2GPI bound FXI in vitro and inhibited its activation to FXIa by thrombin and FXIIa. The affinity of the interaction between ␤2GPI and FXI was equivalent to the interaction between FXI and high molecular weight kininogen. Inhibition of FXI activation occurred with lower concentrations of ␤2GPI than found in human plasma. Proteolytic clipping of ␤2GPI by plasmin abolished its inhibition of FXI activation. The results suggest a mechanism of regulation whereby physiological concentrations of ␤2GPI may attenuate thrombin generation in vivo by inhibition of FXI activation. Plasmin cleavage of ␤2GPI provides a negative feedback that counteracts its inhibition of FXI activation. ␤ 2 -Glycoprotein I (␤ 2 GPI) (also known as Apolipoprotein H, Apo H) is a plasma glycoprotein of 50 kDa that circulates in plasma at Ϸ4 M. ␤ 2 GPI has 326 amino acids and consists of repeated sequences in a form typical of the complement control protein (CCP) module. Individual modules are also known as short consensus repeats (SCR), a key feature of which is disulphide bridges joining the first to third and second to fourth cysteine residues (1) (2) (3) (4) . The first four domains have four cysteines and Ϸ60 aa each. The fifth domain contains an extra disulphide bond and C-terminal extension of 20 aa where the terminating cysteine forms a disulphide bridge (5) . ␤ 2 GPI has affinity for negative charged macromolecules such as anionic phospholipids and proteoglycans. Within domain 5 the region Cys-281-Cys-288 is critical for phospholipid and heparin binding and is highly conserved (6) (7) (8) (9) (10) . The C-terminal extension in the fifth domain is surface exposed and susceptible to proteolytic cleavage (9) . We have previously reported that ␤ 2 GPI is proteolytically clipped between Lys-317 and Thr-318 in the fifth domain abolishing binding to anionic phospholipids (7) . The cleavage at Lys-317-Thr-318 is generated in vitro by plasmin and at low efficiency by activated factor X (FXa) and in vivo in pathological states of increased fibrinolysis (11) (12) (13) . ␤ 2 GPI is the primary target antigen recognized by autoantibodies in patients with the antiphospholipid syndrome (APS) (14, 15) . APS is characterized by recurrent thrombotic events, miscarriages, thrombocytopenia, and the presence of antiphospholipid antibodies (6, 16, 17) . Binding of autoantibodies to ␤ 2 GPI is now generally accepted as an important feature of APS, and a number of studies have shown there is a significant correlation between thrombotic manifestations and the presence of anti-␤ 2 GPI antibodies (17) . Although the physiological function of ␤ 2 GPI in normal individuals remains to be elucidated, plasma from ␤ 2 GPI knockout mice exhibits impaired thrombin generation in vitro (18) . ␤ 2 GPI has both pro-and anticoagulant properties when examined in vitro. It inhibits the generation of FXa in the presence of activated platelets (19) , prothrombinase activity (20) , and the ADP-mediated aggregation of platelets (21) . The in vitro anticoagulant activity of activated protein C (APC) is also inhibited by ␤ 2 GPI (22) . Furthermore, it has been proposed that ␤ 2 GPI can influence the activity of lipoprotein lipase (23) and apoptosis (24) . The association of ␤ 2 GPI with multiple procoagulant and anticoagulant effects may result from its ability to bind anionic phospholipids on activated platelets and endothelial cells. ␤ 2 GPI may act by competing with coagulation factors for phospholipid surfaces (17) .
The contact pathway of coagulation is initiated with activation of FXII by contact with negatively charged surfaces (25) . FXIIa in turn cleaves FXI to FXIa in the presence of high molecular weight kininogen (HK) and prekallikreine (PK). Although previous studies showed that ␤ 2 GPI inhibits the phospholipid mediated autoactivation of FXII (26) and the contact activation pathway of coagulation (27) , the mechanism by which ␤ 2 GPI acts on this pathway has not been determined. We now report that ␤ 2 GPI binds FXI in vitro and inhibits activation to FXIa by thrombin and FXIIa. In vivo activation of FXI by thrombin is thought to be an important mechanism by which coagulation is accelerated via components of the contact activation pathway. Thus, ␤ 2 GPI may attenuate the contact activation pathway by inhibiting activation of FXI by thrombin. Moreover, because ␤ 2 GPI is the dominant autoantigen in patients with APS, dysregulation of this pathway by autoantibodies may be an important mechanism for thrombosis in patients with APS.
Experimental Procedures
Proteins. Plasma-derived FXI, FXIa, HK (single chain), and FXIIa were purchased from Calbiochem-Novabiochem. Substrates S2366 and S2302 were obtained from Chromogenix Instrumentation Laboratory (Milan, Italy). Spectrozyme TH was acquired from American Diagnostica (Greenwich, CT). Kaolin was purchased from Gradipore (Sydney). Hirudin, thrombin, polybrene (Hexadimethrine Bromide), human serum albumin (HSA), BSA, plasmin, phosphatidylserine (PS), and dextran sulfate (DS) (500,000 Da) were purchased from Sigma. ␤ 2 GPI-deficient plasma was purchased from Affinity Biologicals (Ancaster, ON, Canada). Plasma-derived native ␤ 2 GPI (n␤ 2 GPI) was purchased from Haematologic Technologies (Essex Junction, VT) or purified in our laboratory by using cardiolipin affinity chromatography as described (14) or by a sequential protocol with perchloric acid precipitation (28) , cation exchange chromatography (14) , heparin affinity chromatogra-phy (28) , and gel filtration with Sephacryl S-300. A preparation of n␤ 2 GPI proteolytically clipped by plasmin at Lys-317-Thr-318 was generated as described (10) . Recombinant human ␤ 2 GPI (rh␤ 2 GPI) was produced as described (9, 29 I-FXI to immobilized rh␤ 2 GPI was performed by using Lockwell microtiter plates (Nunc) as described (31) . The microtiter wells were coated with 100 l of n␤ 2 GPI, rh␤ 2 GPI, or HSA (3.12-200 nM) by incubation overnight at 4°C. Plates were washed five times with PBS͞0.1%Tween-20 (PBST) by using an automated microplate washer (Beckman Coulter). The wells were blocked with 2% BSA͞PBST for 2 h at 25°C and then washed five times with PBST and five times with PBS. One hundred microliters of I-FXI to immobilized ␤ 2 GPI or HK (single chain) was performed by using Lockwell microtiter plates. The wells were coated with 100 l of rh␤ 2 GPI, n␤ 2 GPI, HK, or BSA (100 nM) by incubation overnight at 4°C. The plate was washed as described above, then 100 l of various concentrations (0.08-40 nM) of 125 I-FXI was added and processed as above. A dissociation constant (K d ) was calculated by nonlinear regression (GRAPHPAD PRISM 3.03, GraphPad, San Diego).
Competitive inhibition of 125 I-FXI binding to immobilized rh␤2GPI by using fluid phase ␤2GPI. Effects of n␤ 2 GPI and rh␤ 2 GPI on the binding of 125 I-FXI to rh␤ 2 GPI were studied by using Lockwell microtiter plates, the wells of which were coated with 100 l of rh␤ 2 GPI (50 nM) by incubation overnight at 4°C. The wells were washed and blocked as described above, then 50 l of either ␤ 2 GPI or BSA (1.3 nM-20 M in 0.5% BSA͞PBS) was added with 50 l of 125 I-FXI (560 pM) and the wells were incubated 4-5 h at 25°C. The wells were thoroughly washed with 0.5% BSA͞PBS, air dried, and counted in a ␥ counter. The number of cpm bound were measured and converted to percentage of total binding by dividing by the cpm bound in the absence of ␤ 2 GPI competitor. The IC 50 was calculated by nonlinear regression (one site binding model, GRAPHPAD PRISM 3.03). Amidolytic assay of thrombin, FXIa, and FXIIa in the presence of ␤2GPI. To determine whether ␤ 2 GPI affects the amidolytic assay of thrombin, FXIIa, or FXIa, incubations were carried out by using the chromogenic substrates Spectrozyme TH, S2302, and S2366 in the presence of thrombin, FXIIa, or FXIa, respectively. Briefly, thrombin (2 nM), FXIIa (20 nM), or FXIa (0.83 nM) was incubated with ␤ 2 GPI or BSA (10 M) for 5 min at 37°C. Incubation mixtures were then diluted 1:5 with TBSA (50 mM Tris⅐HCl͞150 mM NaCl͞0.1% BSA, pH 7.6) and 100 l of each substrate (Spectrozyme TH, 0.50 mM; S2302, 0.24 mM; and S2366, 1.2 mM) was added to 100 l of the incubation mixture. The reactions were incubated for 1 h at 25°C, and the optical density was measured at 405 nm by using a Microplate Scanning Spectrophotometer (Bio-Tek Instruments, Winooski, VT). Activation of FXI by thrombin or FXIIa in the presence of DS. Activation of FXI by thrombin or FXIIa was carried out in TBSA with various concentrations of DS (500,000 Da) as described (32, 33) , with some modifications. Briefly, FXI (60 nM) was mixed with rh␤ 2 GPI or BSA (1 M) and various concentrations of DS (0-5 g͞ml) in TBSA. The mixtures were then incubated for 5 min at 37°C, followed by addition of thrombin (2 nM) or FXIIa (2 nM) and incubation for 5-10 min at 37°C. Reactions were stopped by chilling on ice and diluting 1:5 with TBS. For the reactions using thrombin as activator, hirudin (final concentration, 25 units͞ml) was added to quench thrombin activity. For the reactions using FXIIa as activator, polybrene (final concentration, 200 g͞ml) was added to neutralize the DS. One hundred-microliter aliquots of each reaction mixture were dispensed into individual microtiter wells and mixed with 100 l of S2366 (1.2 mM). The optical density was measured at 405 nm by using a Microplate Scanning Spectrophotometer. The amount of FXIa generated was derived from a standard curve constructed with known concentrations of FXIa. There was a linear correlation between OD 405 and the amount of FXIa that was 0.06-0.32 pmol (r 2 ϭ 0.9984) with thrombin as activator and 0.02-0.1 pmol (r 2 ϭ 0.9950) with FXIIa as activator. Activation of FXI by thrombin or FXIIa: Effect of rh␤2GPI. Activation of FXI by thrombin or FXIIa was carried out in TBSA as described by Baglia and Walsh (32) with some modifications. Briefly, FXI (60 nM), DS (1 g͞ml), and various concentrations of rh␤ 2 GPI or BSA (0.016-10 M) in TBSA were mixed together and incubated for 5 min at 37°C, followed by the addition of thrombin (2 nM) or FXIIa (2 nM) and incubation for a further 5-10 min at 37°C. Reaction mixtures and results were treated as described above. Data fitted a one site binding model, and IC 50 was calculated by nonlinear regression (GRAPHPAD PRISM 3.03).
Activation of FXI by thrombin: Effect of n␤2GPI and clipped (c) n␤2GPI.
Because ␤ 2 GPI proteolytically cleaved between Lys-317 and Thr-318 abolishes its anionic phospholipid binding, we assessed the binding of cn␤ 2 GPI to FXI and its effect on thrombin induced activation of FXI. Binding of 125 I-FXI (25 nM) to immobilized intact and cn␤ 2 GPI (100 nM) was performed as indicated above. Activation of FXI by thrombin in the presence of n␤ 2 GPI or cn␤ 2 GPI (1 M) and quantitation of generated FXIa was performed as described above. Activation of 125 I-FXI in ␤2GPI-deficient human plasma. Activation of FXI was assessed in human plasma deficient in ␤ 2 GPI in the presence of kaolin, which activates FXII. Activation of FXI was assessed by a semiquantitative analysis of 125 I-FXIa according to the protocol described by Brunnee et al. (34) . FXI was radiolabeled with 125 Iodine as described above to a specific activity of 5.5 ϫ 10 16 cpm͞mol. ␤ 2 GPI-deficient human plasma was reconstituted by the addition of rh␤ 2 GPI or BSA to a final concentration of 1.5 M, then 125 I-FXI was added to the reconstituted plasma at a final concentration of 2 nM. The mixtures were incubated for 1 min at 37°C followed by adding an equal volume of Kaolin diluted 2-fold in Tris⅐HCl buffer (50 mM Tris⅐HCl͞150 mM NaCl, pH 7.6). The mixtures were incubated at 37°C, and at defined time points, 5-l aliquots were removed and the reaction was stopped by snap freezing the samples. Aliquots at each time point were snap thawed into SDS͞PAGE (4-12%) and run under reducing conditions to resolve 125 I-FXI and 
Saturation binding of 125 I-rh␤2GPI to DS and an anti-␤2GPI antibody.
Saturation binding of 125 I-rh␤ 2 GPI to immobilized DS and anti-␤ 2 GPI antibody (moAb1) (35) was performed by using Lockwell microtiter plates, the wells of which were coated with 100 l of moAb1, DS, or BSA (100 nM) by incubation overnight at 4°C. The plate was washed five times with PBS and residual binding sites in the wells were blocked with 2% BSA͞PBS for 2 h at 25°C. The plate was washed five times with PBS. One hundred microliters of 125 I-rh␤ 2 GPI (1.56-200 nM) in 0.5% BSA͞PBS was added to individual wells and incubated for 4 h at 25°C. The wells were thoroughly washed with 0.5% BSA͞PBS, air dried, and counted in a ␥ counter. The number of cpm were measured and converted to pmol of the rh␤ 2 GPI bound. The K d was calculated by nonlinear regression (GRAPHPAD PRISM 3.03).
Binding of 125 I-rh␤2GPI to PS or DS.

125
I-rh␤ 2 GPI (20 nM) binding to immobilized PS, BSA, or DS was performed by using Lockwell microtiter plates, the wells of which were coated with 100 l of PS (5 g͞ml), DS (5 g͞ml), or BSA (5 g͞ml) by incubation overnight at 4°C. The plate was then processed as indicated above for 125 I-rh␤ 2 GPI binding to DS. The number of cpm bound were measured and converted to pmol of ␤ 2 GPI bound. Statistical analysis. Data are expressed as mean Ϯ SD. Differences between groups were evaluated by using Student's t test.
Results
FXI Binds Immobilized Native and Recombinant ␤2GPI.
125
I-FXI bound to rh␤ 2 GPI, n␤ 2 GPI, and HK (data not shown) in a dose-dependent manner, reaching a plateau at 50-100 nM of protein (Fig. 1) .
FXI circulates in plasma as a noncovalent complex with HK (36). Our preliminary experiments showed that the amount of 125 I-FXI binding to HK was higher than to ␤ 2 GPI, so we carried out saturation binding experiments to compare the capacity of (Fig. 2) .
rh␤2GPI Inhibits Activation of FXI in the Presence of DS. The observation that FXI bound to ␤ 2 GPI led us to evaluate the effects of ␤ 2 GPI on activation of FXI by thrombin and FXIIa. In the presence of DS, FXI can be activated by FXIIa as well as by thrombin (32, 33) . The optimal concentration of DS for activation of FXI was 1-2 g͞ml (data not shown).
␤ 2 GPI inhibited FXI activation by thrombin and FXIIa ( Fig.  3) with an IC 50 of 1.39 and 0.79 M, respectively. In the absence of inhibitor, 0.170 and 0.058 pmol of FXIa was generated with thrombin and FXIIa, respectively. ␤ 2 GPI did not influence the enzymatic activity of FXIIa, thrombin, or FXIa in the amidolytic assay with their respective specific chromogenic substrates (data not shown).
␤2GPI Proteolytically Clipped at Lys-317-Thr-318 Binds FXI but Does
Not Inhibit Its Activation by Thrombin. To determine whether the cn␤ 2 GPI bound FXI as efficiently as n␤ 2 GPI, we used binding experiments with a constant concentration of 125 I-FXI (25 nM) added to wells coated with cn␤ 2 GPI or n␤ 2 GPI. FXI bound to n␤ 2 GPI as efficiently as it did to cn␤ 2 GPI (P ϭ 0.9; n ϭ 6) (Fig.  4A) . The observation that cn␤ 2 GPI bound FXI led us to assess the activation of FXI by thrombin in the presence of cn␤ 2 GPI. The clipped preparation did not cause any inhibition, whereas n␤ 2 GPI inhibited thrombin activation of FXI by 75% (P ϭ 0.001; n ϭ 4) (Fig. 4B) . I-FXI; mean Ϯ SD; n ϭ 3) than in ␤ 2 GPI-deficient plasma (Fig. 5 A and B) (P ϭ 0.01).
␤2GPI Inhibits Activation of FXI by Thrombin and FXIIa but Does Not
Bind to DS. The ability of ␤ 2 GPI to inhibit activation of FXI by thrombin or FXIIa in the presence of DS was not overcome by increasing the DS concentration (data not shown). This result suggested that ␤ 2 GPI does not inhibit FXI activation by competing for binding to DS. ␤ 2 GPI bound to the anti-␤ 2 GPI antibody moAb1 but not DS in saturation binding experiments and in direct binding experiments bound PS but not DS or BSA (Fig. 6 A and B) .
Discussion
Although the physiological function of ␤ 2 GPI has not been deduced, plasma from ␤ 2 GPI null mice exhibits significantly diminished in vitro thrombin generation compared with plasma from ␤ 2 GPI wild-type mice (18) , implying that ␤ 2 GPI may have an important in vivo role in the generation of thrombin. We have examined the interaction between ␤ 2 GPI and FXI in the context of previous studies showing that ␤ 2 GPI inhibits the contact activation pathway and other downstream coagulation reactions including the generation of FXa. We report that ␤ 2 GPI binds FXI and inhibits its activation to FXIa by thrombin and FXIIa. Inhibition of FXI activation occurred in the presence of DS and was demonstrated with concentrations of ␤ 2 GPI much lower than normally found in human plasma. The inhibition was dose-dependent and reached 100% at 10 M.
The C-terminal loop region of ␤ 2 GPI is surface exposed and is susceptible to cleavage by the proteases plasmin and FXa. Cleavage at Lys-317-Thr-318 of the polypeptide chain exists with the two cleaved segments linked by a disulphide bonded complex (7) . This cleavage alters the spatial array of the three critical Lys residues and abolishes the ability of ␤ 2 GPI to bind anionic phospholipid surfaces (7) . It has previously been reported that cleavage of ␤ 2 GPI at Lys-317-Thr-318 disturbs the nearby electrostatic environment (37) . It is believed that the integrity of the 317͞318 peptide bond is important in tethering the cluster of positively charged and hydrophobic residues in this region. Although the hydrophobic C-terminal loop is important in phospholipid binding, a preparation of n␤ 2 GPI cleaved at Lys-317-Thr-318 by plasmin bound to FXI just as well as n␤ 2 GPI but did not inhibit the activation of FXI by thrombin (Fig. 4 A  and B) . ␤ 2 GPI is often clipped at Lys-317-Thr-318 in plasma of patients with lupus anticoagulant and in disseminated intravascular coagulation (DIC) (12, 13) . The clipped form of ␤ 2 GPI correlated with in vitro markers of fibrinolytic activity. Thus, in vivo the clipped form is most likely generated by plasmin. The C-terminal hydrophobic loop of c␤ 2 GPI has been confirmed by heteronuclear magnetic resonance to be tightly fixed by electrostatic interaction with the lysine cluster at the phospholipid binding site while at the same time enhancing stability and neutralizing the positive charge in this region (37) . Thus, the C-terminal loop of the intact ␤ 2 GPI is more mobile than that of the clipped molecule, allowing a better interaction with FXI͞ thrombin complexes, which may explain why c␤ 2 GPI binds FXI but does not inhibit its activation by thrombin.
Both ␤ 2 GPI and FXI contain protein modules. In FXI these consist of Ϸ90 amino acids each, are located at the N terminus, and are commonly termed apple domains. The apple domains mediate binding with other proteins and proteoglycans. Although this study did not investigate domain-specific interactions between FXI and ␤ 2 GPI, we noted that the interaction was not affected by HK (data not shown), suggesting that HK and ␤ 2 GPI bind to different sites on FXI. There was no binding of HK to ␤ 2 GPI (data not shown).
Platelet-bound FXIa converts FIX by proteolytic cleavage to its active form, FIXa. FIX is a zymogen form of a protease critical to regulation of blood coagulation (38) that may also be activated by the complex of tissue factor with FVIIa (39, 40) . FXI circulates in human plasma as a covalent dimer of two identical 80-kDa molecules and lacks the Gla domain that is characteristic of plasma coagulation proteases (41) . It has been proposed that FXI functions by binding the catalytic surface of platelets with one polypeptide, whereas the other polypeptide interacts with FIX (42) . Clotting factors that are protease zymogens such as FIX are typically activated in the presence of a protein cofactor plus divalent cations and an appropriate procoagulant phospholipid surface. Interestingly, no protein cofactor has been identified that is required for FIX activation, and its activation is not inf luenced by the addition of phospholipid.
␤ 2 GPI at physiological concentrations has been demonstrated to inhibit the generation of FXa in the presence of activated gel filtered platelets (19) . Activated platelets provide an appropriate in vivo procoagulant surface for assembly of surface-bound protease substrate complexes. Moreover, activated platelets rather than endothelial cells are the preferred procoagulant surface for binding and activating FXI, which is critical for the initiation of the consolidation phase of coagulation (41) . FXI͞FXIa binds activated platelets in a saturable and reversible manner in the presence of either HK and zinc ions (43, 44) or prothrombin and calcium ions (45) . Plateletbound FXI can be activated by FXIa, thrombin, or FXIIa, although the preferred in vivo activator is most likely thrombin (41) . Thus, activation of FXI on activated platelet surfaces by thrombin accelerates coagulation by the sequential activation of FIXa and FXa.
The effect of ␤ 2 GPI on FXI activation by thrombin and FXIIa has major implications for understanding the role of ␤ 2 GPI in coagulation and the prothrombotic diathesis seen in patients with APS. Whereas ␤ 2 GPI inhibits generation of FXa on activated platelets, antiphospholipid antibodies are known to interfere with this inhibition, thereby increasing FXa generation (19) . Inhibition of FXI activation by ␤ 2 GPI using a system with purified coagulation factors and in human ␤ 2 GPIdeficient plasma provides a regulatory mechanism for FXa and thrombin generation in vivo. The demonstration that ␤ 2 GPI binds FXI and inhibits its activation by thrombin and FXIIa provides a possible alternative explanation for the thrombosis in patients with APS. Specifically, antiphospholipid antibodies that generally have low affinity for antigen may efficiently bind platelet-associated ␤ 2 GPI, thereby blocking its attenuating effect on FXI activation.
Although FXI is not essential for haemostasis, unlike coagulation factors of the extrinsic and common pathways, FXI activity is essential for certain in vivo thrombosis models in rabbits (46) and mice (47) , as well as in the early postnatal mortality observed in protein C-deficient mice (48) . In a recent report, FXI was demonstrated to be essential for thrombus propagation in a primate arterial thrombosis model (49) . In that study, the authors concluded that extension of thrombi in vivo was dependent on the activation of FXI. Interestingly, elevated levels of FXI have been reported to be an independent risk factor for both venous and arterial thrombosis in humans (45, 46) .
We have demonstrated that ␤ 2 GPI can bind FXI and inhibit the activation of FXI by thrombin and FXIIa. Secondly, we have demonstrated that cn␤ 2 GPI can bind FXI but does not inhibit its activation by thrombin. We propose that ␤ 2 GPI is a physiological inhibitor of FXI activation in vivo and that cn␤ 2 GPI is part of the positive feedback loop in FXI activation.
We propose that this interaction may be important in vivo and that the inhibition of this effect by antiphospholipid antibodies may be an important mechanism for thrombosis in patients with APS. 
